CD79B and marginal zone lymphoma: The majority of the alterations in these genes appear to be activating mutations, including truncating mutations with potential gain-of-function in BCL10. Alterations in BCL10, CARD11, and MYD88 have been implicated in ocular MZL pathogenesis [8], and CD79B somatic changes in splenic MZL [9] have been reported.